Effect of dehydroepiandrosterone on atopic dermatitis-like skin lesions induced by 1-chloro-2,4-dinitrobenzene in mouse

Journal of Dermatological Science

Volumn 72, Issue 2, 2013, Pages 149-157

  Chan, Cheng Chi ^a   Liou, Chian Jiun ^b   Xu, Pei Yin ^b   Shen, Jiann Jong ^a,c   Kuo, Ming Ling ^a   Len, Wen Bin ^b   Chang, Liang En ^b   Huang, Wen Chung ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Atopic dermatitis; Chemokine; Cytokine; Dehydroepiandrosterone; Eosinophil

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; CHEMOKINE; CYTOKINE; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE; PRASTERONE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; IMMUNOLOGICAL ADJUVANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CELL CULTURE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DERMATITIS; EOSINOPHIL; FEMALE; HORMONE ACTION; HORMONE INHIBITION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; IN VITRO STUDY; INTRACELLULAR SIGNALING; KERATINOCYTE; MAST CELL; MOUSE; NONHUMAN; OTITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROVOCATION TEST; SKIN; SKIN BIOPSY; SKIN DEFECT; SKIN SENSITIZATION; SKINFOLD THICKNESS; SPLEEN CELL; TH2 CELL; TREATMENT OUTCOME; ANIMAL; BAGG ALBINO MOUSE; CYTOLOGY; DERMATITIS, ATOPIC; DRUG EFFECTS; INFLAMMATION; METABOLISM; PHOSPHORYLATION; SPLEEN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTI-INFLAMMATORY AGENTS; CHEMOKINES; CYTOKINES; DEHYDROEPIANDROSTERONE; DERMATITIS, ATOPIC; DINITROCHLOROBENZENE; EOSINOPHILS; FEMALE; HUMANS; INFLAMMATION; KERATINOCYTES; MAST CELLS; MICE; MICE, INBRED BALB C; PHOSPHORYLATION; SKIN; SPLEEN; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885053138     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2013.06.015     Document Type: Article

References (49)

1. Denby K.S., Beck L.A. Update on systemic therapies for atopic dermatitis. Curr Opin Allergy Clin Immunol 2012, 12:421-426.
2. Bieber T. Atopic dermatitis. N Engl J Med 2008, 358:1483-1494.
3. Kubo A., Nagao K., Amagai M. Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases. J Clin Invest 2012, 122:440-447.
4. Berke R., Singh A., Guralnick M. Atopic dermatitis: an overview. Am Fam Physician 2012, 86:35-42.
5. Gittler J.K., Krueger J.G., Guttman-Yassky E. Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis. J Allergy Clin Immunol 2013, 131:300-313.
6. Turner M.J., Travers J.B., Kaplan M.H. T helper cell subsets in the development of atopic dermatitis. J Drugs Dermatol 2012, 11:1174-1178.
7. Brandt E.B., Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol 2011, 2:pii:110.
8. Tokura Y. Extrinsic and intrinsic types of atopic dermatitis. J Dermatol Sci 2010, 58:1-7.
9. Bieber T., Cork M., Reitamo S. Atopic dermatitis: a candidate for disease-modifying strategy. Allergy 2012, 67:969-975.
10. Schmitt J., von Kobyletzki L., Svensson A., Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 2011, 164:415-428.
11. Guglielmetti S., Dart J.K., Calder V. Atopic keratoconjunctivitis and atopic dermatitis. Curr Opin Allergy Clin Immunol 2010, 10:478-485.
12. Wollenberg A., Ehmann L.M. Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol 2012, 24:253-260.
13. Hsu C.J., Wang L.F. Emerging treatment of atopic dermatitis. Clin Rev Allergy Immunol 2007, 33:199-203.
14. Arnold J.T. DHEA metabolism in prostate: for better or worse?. Mol Cell Endocrinol 2009, 301:83-88.
15. Boxer R.S., Kleppinger A., Brindisi J., Feinn R., Burleson J.A., Kenny A.M. Effects of dehydroepiandrosterone (DHEA) on cardiovascular risk factors in older women with frailty characteristics. Age Ageing 2010, 39:451-458.
16. Rege J., Rainey W.E. The steroid metabolome of adrenarche. J Endocrinol 2012, 214:133-143.
17. Rizvi S.I., Jha R. Strategies for the discovery of anti-aging compounds. Expert Opin Drug Discov 2011, 6:89-102.
18. Sorwell K.G., Urbanski H.F. Dehydroepiandrosterone and age-related cognitive decline. Age (Dordr) 2010, 32:61-67.
19. Tworoger S.S., Missmer S.A., Eliassen A.H., Spiegelman D., Folkerd E., Dowsett M., et al. The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women. Cancer Epidemiol Biomarkers Prev 2006, 15:967-971.
20. Forsblad-d'Elia H., Carlsten H., Labrie F., Konttinen Y.T., Ohlsson C. Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. J Clin Endocrinol Metab 2009, 94:2044-2051.
21. Lowin T., Weidler C., Jenei-Lanzl Z., Capellino S., Baerwald C.G., Buttgereit F., et al. Relationship between placenta growth factor 1 and vascularization, dehydroepiandrosterone sulfate to dehydroepiandrosterone conversion, or aromatase expression in patients with rheumatoid arthritis and patients with osteoarthritis. Arthritis Rheum 2012, 64:1799-1808.
22. Kanazawa I., Yamaguchi T., Sugimoto T. Effects of intensive glycemic control on serum levels of insulin-like growth factor-I and dehydroepiandrosterone sulfate in type 2 diabetes mellitus. J Endocrinol Invest 2012, 35:469-472.
23. Sato K., Iemitsu M., Aizawa K., Mesaki N., Ajisaka R., Fujita S. DHEA administration and exercise training improves insulin resistance in obese rats. Nutr Metab 2012, 9:47.
24. Sulcova J., Stulc T., Hill M., Hampl R., Masek Z., Vondra K., et al. Decrease in serum dehydroepiandrosterone level after fenofibrate treatment in males with hyperlipidemia. Physiol Res 2005, 54:151-157.
25. Liou C.J., Huang W.C. Dehydroepiandrosterone suppresses eosinophil infiltration and airway hyperresponsiveness via modulation of chemokines and Th2 cytokines in ovalbumin-sensitized mice. J Clin Immunol 2011, 31:656-665.
26. Liou C.J., Huang W.C., Kou M.L., Yang R.C., Shen J.J. Long-term oral administration of Gynostemma pentaphyllum extract attenuates airway inflammation and Th2 cell activities in ovalbumin-sensitized mice. Food Chem Toxicol 2010, 48:2592-2598.
27. Huang W.C., Liou C.J. Dietary acacetin reduces airway hyperresponsiveness and eosinophil infiltration by modulating eotaxin-1 and Th2 cytokines in a mouse model of asthma. Evid Based Complement Alternat Med 2012, 2012:910520.
28. Huang W.C., Kuo M.L., Li M.L., Yang Y.C., Liou C.L., Shen J.J. The extract of Gynostemma pentaphyllum enhanced the production of antibodies and cytokines in mice. Yakugaku Zasshi 2007, 127:889-896.
29. Huang W.C., Kuo M.L., Li M.L., Yang R.C., Liou C.J., Shen J.J. Gynostemma pentaphyllum decreases allergic reactions in a murine asthmatic model. Am J Chin Med 2008, 36:579-592.
30. Chang W.T., Huang W.C., Liou C.J. Evaluation of the anti-inflammatory effects of phloretin and phlorizin in lipopolysaccharide-stimulated mouse macrophages. Food Chem 2012, 134:972-979.
31. Kuo I.H., Yoshida T., De Benedetto A., Beck L.A. The cutaneous innate immune response in patients with atopic dermatitis. J Allergy Clin Immunol 2013, 131:266-278.
32. Boguniewicz M., Leung D.Y. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011, 242:233-246.
33. de Bruin Weller M.S., Knulst A.C., Meijer Y., Bruijnzeel-Koomen C.A., Pasmans S.G. Evaluation of the child with atopic dermatitis. Clin Exp Allergy 2012, 42:352-362.
34. Guttman-Yassky E., Nograles K.E., Krueger J.G. Contrasting pathogenesis of atopic dermatitis and psoriasis-Part I: Clinical and pathologic concepts. J Allergy Clin Immunol 2011, 127:1110-1118.
35. Guttman-Yassky E., Nograles K.E., Krueger J.G. Contrasting pathogenesis of atopic dermatitis and psoriasis-Part II: Immune cell subsets and therapeutic concepts. J Allergy Clin Immunol 2011, 127:1420-1432.
36. Yang G., Choi C.H., Lee K., Lee M., Ham I., Choi H.Y. Effects of Catalpa ovata stem bark on atopic dermatitis-like skin lesions in NC/Nga mice. J Ethnopharmacol 2013, 145:416-423.
37. Tanaka A., Jung K., Matsuda A., Jang H., Kajiwara N., Amagai Y., et al. Daily intake of Jeju groundwater improves the skin condition of the model mouse for human atopic dermatitis. J Dermatol 2013, 40:193-200.
38. Choi J.H., Kim H.G., Jin S.W., Han E.H., Khanal T., Do M.T., et al. Topical application of Pleurotus eryngii extracts inhibits 2,4-dinitrochlorobenzene-induced atopic dermatitis in NC/Nga mice by the regulation of Th1/Th2 balance. Food Chem Toxicol 2013, 53:38-45.
39. Matsuda A., Tanaka A., Pan W., Okamoto N., Oida K., Kingyo N., et al. Supplementation of the fermented soy product ImmuBalance effectively reduces itching behavior of atopic NC/Tnd mice. J Dermatol Sci 2012, 67:130-139.
40. Rothenberg M.E., Hogan S.P. The eosinophil. Annu Rev Immunol 2006, 24:147-174.
41. Lawson C., Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol Rep 2009, 61:22-32.
42. Frew A.J. Allergen immunotherapy. J Allergy Clin Immunol 2010, 125:S306-S313.
43. Hayashida S., Uchi H., Takeuchi S., Esaki H., Moroi Y., Furue M. Significant correlation of serum IL-22 levels with CCL17 levels in atopic dermatitis. J Dermatol Sci 2011, 61:78-79.
44. Shimada Y., Takehara K., Sato S. Both Th2 and Th1 chemokines (TARC/CCL17, MDC/CCL22, and Mig/CXCL9) are elevated in sera from patients with atopic dermatitis. J Dermatol Sci 2004, 34:201-208.
45. Hashimoto S., Nakamura K., Oyama N., Kaneko F., Tsunemi Y., Saeki H., et al. Macrophage-derived chemokine (MDC)/CCL22 produced by monocyte derived dendritic cells reflects the disease activity in patients with atopic dermatitis. J Dermatol Sci 2006, 44:93-99.
46. Furukawa H., Takahashi M., Nakamura K., Kaneko F. Effect of an antiallergic drug (Olopatadine hydrochloride) on TARC/CCL17 and MDC/CCL22 production by PBMCs from patients with atopic dermatitis. J Dermatol Sci 2004, 36:165-172.
47. Saeki H., Tamaki K. Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. J Dermatol Sci 2006, 43:75-84.
48. Ruland J. Return to homeostasis: downregulation of NF-kappaB responses. Nat Immunol 2011, 12:709-714.
49. Oeckinghaus A., Hayden M.S., Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nat Immunol 2011, 12:695-708.